Cellectar Biosciences
- CLR 125 Ph1 interimMid-2026CLR 125 Ph1 interim, Mid-2026, major
- CLR 125 interimMid-2026CLR 125 interim, Mid-2026, major
- Iopofosine I 131 WM filing3Q 2026Iopofosine I 131 WM filing, 3Q 2026, material
- Iopofosine I 131 filing3Q 2026Iopofosine I 131 filing, 3Q 2026, material
- FinancingLate 2026 / early 2027Financing, Late 2026 / early 2027, routine
- Iopofosine I 131 Ph3 startEarly 2027Iopofosine I 131 Ph3 start, Early 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (6 active programs)
iopofosine I 131
CLR 131CLR 125
CLR 121125CLR 225
CLR 121225Technology platforms
PDC
Phospholipid Drug Conjugate (PDC) delivery platform engineered to target and gain intracellular access to primary tumors, metastatic sites, and cancer stem cells; can be conjugated with small-molecule chemotherapeutics, radiotherapeutics, and other therapeutic molecules; focus areas include hematologic cancers and solid tumors
Phospholipid Drug Conjugate
PDC (Phospholipid Drug Conjugate) delivery platform for cancer cell-targeting treatments; enables targeted delivery of radioisotopes and chemotherapeutics to cancer cells with improved efficacy and reduced off-target effects across multiple oncology indications
Discontinued (3)
- iopofosine — Neuroblastoma
- iopofosine — Osteosarcoma
- iopofosine — Ewing's Sarcoma
Biotech Distilled coverage (2)
- 2026-08-14 UPDATE: Cellectar Biosciences (CLRB) - The Warrants Went Live 🔒 Paid
- 2026-05-07 Cellectar Biosciences (CLRB) - Scientific Deep Dive for Iopofosine and Pipeline Products
Articles open on Substack. Some deep dives are subscriber-only.